April 21, 2019 - Parkinson’s Weekly Update

April 21, 2019 – Parkinson’s Weekly Update

Major Tom to Ground Control ... this week’s report comes from  somewhere over the North Atlantic Ocean at an altitude of 36,000 feet, where we are currently testing air turbulence therapy for Parkinson’s Disease ... so apologies in advance for any and all typos. In an otherwise slow holiday week, University of Cambridge researchers are suggesting that an existing high blood pressure medication, felodipine, might be repurposed to treat Parkinson’s Disease. This study reminds me of another high blood pressure medication, isradipine, also a calcium channel blocker, which saw positive results in an animal model study 12 years ago. Since ...
Isradipine Phase 3 Study Results Expected Soon (Result: FAIL)

Isradipine Phase 3 Study Results Expected Soon (Result: FAIL)

In an otherwise slow holiday week, University of Cambridge researchers are suggesting that an existing high blood pressure medication might be repurposed to treat Parkinson’s Disease. Felodipine, at proportionally low doses was able to induce autophagy and clean out misfolded proteins in a mouse model of Parkinson’s. There is a lot more research needed as more PD research increasingly targets autophagy: https://www.eurekalert.org/pub_releases/2019-04/uoc-bpd041619.php This study reminds me of another high blood pressure medication, isradipine, which saw positive results in an animal model study 12 years ago. Researchers have recently completed a 3 year phase 3 study of isradipine, and these latest ...